Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).
Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Karen Kelly, MD, of the University of California, Davis, summarizes three important papers on NSCLC: expression as a predictive biomarker; pembrolizumab, immune-mediated adverse events, and corticosteroid use; and an evaluation of disease-related symptoms in patients treated with nivolumab or docetaxel (Abstracts ORAL 31.01, 31.02, and 31.03).
Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).
Ramaswamy Govindan, MD, of Washington University, summarizes three important papers: ROVA-T in relapsed and refractory small cell lung cancer, genomic characterization of large-cell neuroendocrine tumors, and the ECOG study on bevacizumab following chemotherapy for resected non–small cell lung cancer.
Silvia Novello, MD, PhD, of the University of Turin, discusses a much-neglected aspect of lung cancer: It is not just the province of men; women are affected in great numbers as well.
